Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results

Stock Information for Citius Oncology Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Citius Oncology Inc.

Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results and Business Highlights
Exagen Inc. to Announce Fourth Quarter and Full-Year 2024 Financial Results on March 11, 2025
Exagen Inc. to Participate in Upcoming Investor Conferences
Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTD
Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform
Exagen Inc. to Participate in Fourth Quarter Investor Conferences
Exagen Inc. Reports Third Quarter 2024 Results
Exagen to Announce Third Quarter 2024 Results on November 12, 2024

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.